Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines

Journal of Immunology

Volumn 178, Issue 7, 2007, Pages 4676-4687

  Galili, Uri ^a   Wigglesworth, Kim ^a   Abdel Motal, Ussama M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA GALACTOSIDASE; CANCER VACCINE; CERAMIDE; EPITOPE; FC RECEPTOR; GLYCOLIPID; OVALBUMIN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE MEMBRANE; GRAFT REJECTION; IMMUNE RESPONSE; KNOCKOUT MOUSE; MELANOMA; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; XENOGRAFT;

EID: 33947682719     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.7.4676     Document Type: Article

References (61)

1. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516-7523.
2. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, H. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
3. Spiotto, M. T., Y. X. Fu, and H. Schreiber. 2003. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15: 725-730.
4. Furumoto, K., L. Soares, E. G. Engleman, and M. Merad. 2004. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113: 774-777.
5. + suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J. Exp. Med. 164: 1179-1192.
6. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
7. Turk, M. J., J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
8. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
9. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
10. Levitsky, H. I., J. Montgomery, M. Ahmadzadeh, K. Staveley-O'Carroll, F. Guarnieri, D. L. Longo, and L. W. Kwak. 1996. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156: 3858-3865.
11. Turk, M. J., J. D. Wolchok, J. A. Guevara-Patino, S. M. Goldberg, and A. N. Houghton. 2002. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188: 122-135.
12. Galili, U., E. A. Rachmilewitz, A. Peleg, and I. Flechner. 1984. A unique natural human IgG antibody with anti-α-galactosyl specificity. J. Exp. Med. 160: 1519-1531.
13. Galili, U., M. R. Clark, S. B. Shohet, J. Buehler, and B. A. Macher. 1987. Evolutionary relationship between the anti-Gal antibody and the Galα1→3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 84: 1369-1373.
14. Galili, U., B. A. Macher, J. Buehler, and S. B. Shohet. 1985. Human natural anti-α-galactosyl IgG, II: the specific recognition of α(1→3)-linked galactose residues. J. Exp. Med. 162: 573-582.
15. Galili, U. 1993. Evolution and pathophysiology of the human natural anti-Gal antibody. Springer Semin. Immunopathol. 15: 155-171.
16. Galili, U., R. E. Mandrell, R. M. Hamadeh, S. B. Shohet, and J. M. Griffis. 1988. Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 56: 1730-1737.
17. Galili, U., S. B. Shohet, E. Kobrin, C. L. M. Stults, and B. A. Macher. 1988. Man, apes, and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263: 17755-17762.
18. Galili, U. 1993. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotranplantation in humans. Immunol. Today 14: 480-482.
19. Good, A. H., D. K. Cooper, A. J. Malcolm, R. M. Ippolito, E. Koren, F. A. Neethling, Y. Ye, N. Zuhdi, and L. R. Lamontagne. 1992. Identification of carbohydrate structures which bind human anti-porcine antibodies: implication for discordant xenografting in man. Transplant. Proc. 24: 559-562.
20. Sandrin, M., H. A. Vaughan, P. L. Dabkowski, and I. F. C. McKenzie. 1993. Anti-pig IgM antibodies in human serum react predominantly with Galα1-3Gal epitopes. Proc. Natl. Acad. Sci. USA 90: 11391-11395.
21. Collins, B. H., A. H. Cotterell, K. R. McCurry, C. G. Alvarado, J. C. Magee, W. Parker, and J. L. Platt. 1995. Cardiac xenografts between primate species provide evidence of the α-galactosyl determinant in hyperacute rejection. J Immunol. 154: 5500-5510.
22. Galili, U., and D. C. LaTemple. 1997. The natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol. Today 18: 281-285.
23. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290.
24. Dhodapkar, K. M., J. Krasovsky, B. Williamson, and D. M. Dhodapkar. 2002. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195: 125-133.
25. Rafiq, K., A. Bergtold, and R. Clynes. 2002. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110: 71-79.
26. Groh, V., Y. Q. Li, D. Cioca, N. N. Hunder, W. Wang, S. R. Riddell, C. Yee, and T. Spies. 2005. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl. Acad. Sci. USA 102: 6461-6466.
27. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189: 371-380.
28. Dhodapkar, K. M., and M. V. Dhodapkar. 2005. Recruiting dendritic cells to improve antibody therapy of cancer. Proc. Natl. Acad. Sci. USA 102: 6243-6244.
29. Boscardin, S. B., J. C. Hafalla, R. F. Masilamani, A. O. Kamphorst, H. A. Zebroski, U. Rai, A. Morrot, F. Zavala, R. M. Steinman, R. S. Nussenzweig, and M. C. Nussenzweig. 2006. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203: 599-606.
30. Thall, A. D., P. Maly, and J. B. Lowe. 1995. Oocyte Galα1-3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J. Biol. Chem. 270: 21437-21442.
31. Tanemura, M., D. Yin, A. S. Chong, and U. Galili. 2000. Differential immune response to α-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J. Clin. Invest. 105: 301-310.
32. Tearle, R. G., M. J. Tange, Z. L. Zannettino, M. Katerelos, T. A. Shinkel, B. J. W. Van Denderen, A. J. Lonie, I. Lyons, M. B. Nottle, T. Cox, et al. 1996. The α-1,3-galactosyltransferase knockout mouse: implications for xenotransplantation. Transplantation 61: 13-19.
33. Gorelik, E., L. Duty, F. Anaraki, and U. Galili. 1995. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3-galactosyltransferase gene transfection. Cancer Res. 55: 4168-4173.
34. Deriy, L., H. Ogawa, G. Gao, and U. Galili. 2005. In vivo targeting of vaccinating tumor cells to antigen presenting cells by a gene therapy method with adenovirus containing the α1-,3-galactosyltransferase gene. Cancer Gene Ther. 12: 528-539.
35. Abdel-Motal, U., S. Wang, S. Lu, K. Wigglesworth, and U. Galili. 2006. Increased immunogenicity of HIV gp120 engineered to express Galα1- 3Galβ1-4GlcNac-R epitopes. J. Virol. 80: 6943-6951.
36. Brown, D. M., T. L. Fisher, C. Wei, J. G. Frelinger, and E. M. Lord. 2001. Tumours can act as adjuvants for humoral immunity. Immunology 102: 486-497.
37. Karttunen, J., S. Sanderson, and N. Shastri. 1992. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. USA 89: 6020-6024.
38. Sanderson, S., and N. Shastri. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6: 369-376.
39. Galili, U., C. B. Basbaum, S. B. Shohet, J. Buehler, and B. A. Macher. 1987. Identification of erythrocyte Galα1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13. J. Biol. Chem. 262: 4683-4688.
40. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
41. Magnani, J. L., M. Brockhaus, D. F. Smith, V. Ginsburg, M. Blaszczyk, K. F. Mitchell, Z. Steplewski, and H. Koprowski. 1981. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 212: 55-56.
42. LaTemple, D. C., J. T. Abrams, S. U. Zhang, and U. Galili. 1999. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knock out mice for α1,3-galactosyltranferase. Cancer Res. 59: 3417-3423.
43. Eto, T., Y. Iichikawa, K. Nishimura, S. Ando, and T. Yamakawa. 1968. Chemistry of lipids of the posthemolytic residue or stroma of erythrocytes, XVI: occurance of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes in rabbit. J. Biochem. 64: 205-213.
44. Stellner, K., H. Saito, and S. Hakomori. 1973. Determination of aminosugar linkage in glycolipids by methylation, aminosugar linkage of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen. Arch. Biochem. Biophys. 133: 464-472.
45. Dabrowski, U., P. Hanfland, H. Egge, S. Kuhn, and J. Dabrowski. 1984. Immunochemistry of I/i-active oligo- and polyglycosylceramides from rabbit erythrocyte membranes: determination of branching patterns of a ceramide pentadecasaccharide by 1H nuclear magnetic resonance. J. Biol. 259: 7648-7651.
46. Egge, H., M. Kordowicz, J. Peter-Katalinic, and P. Hanfland. 1985. Immunochemistry of I/i-active oligo- and polyglycosylceramides from rabbit erythrocyte membranes: characterization of linear, di-, and triantennary neolactoglycosphingolipids. J. Biol. Chem. 260: 4927-4935.
47. Hanfland, P., M. Kordowicz, J. Peter-Katalinic, H. Egge, J. Dabrowski, and U. Dabrowski. 1988. Structure elucidation of blood group B-like and I-active ceramide eicosa- and pentacosasaccharides from rabbit erythrocyte membranes by combined gas chromatography-mass spectrometry; electron-impact and fast-atom-bombardment mass spectrometry; and two-dimensional correlated, relayed-coherence transfer, and nuclear Overhauser effect 500-MHz 1H-n.m.r. spectroscopy. Carbohydr. Res. 178: 1-21.
48. Honma, K., H. Manabe, M. Tomita, and A. Hamada. 1981. Isolation and partial structural characterization of macroglycolipid from rabbit erythrocyte membranes. J. Biochem. 90: 1187-1196.
49. Gorter, A., and S. Meri. 1999. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today 20: 576-582.
50. Fishelson, Z., N. Donin, S. Zell, S. Schultz, and M. Kirschfink. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol. 40: 109-123.
51. Page, G., S. Lebecque, and P. Miossec. 2002. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J. Immunol. 168: 5333-5341.
52. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446.
53. Dhodapkar, K. M., J. L. Kaufman, M. Ehlers, D. K. Banerjee, E. Bonvini, S. Koenig, R. M. Steinman, J. V. Ravetch, and M. V. Dhodapkar. 2005. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102: 2910-2915.
54. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
55. Egilmez, N. K., Y. S. Jong, M. S. Sabel, J. S. Jacob, E. Mathiowitz, and R. B. Bankert. 2000. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 60: 3832-3837.
56. Manches, O., J. Plumas, L. Lui, L. Chaperot, J. P. Molens, J. J. Sotto, J. C. Bensa, and U. Galili. 2005. Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy with autologous tumor cells. Haematologica 90: 625-634.
57. Dhodapkar, K. M., D. Banerjee, and S. M. Steinman. 2005. Harnessing the immune system against human glioma. Ann. NY Acad. Sci. 1062: 13-21.
58. Rossi, G. R., R. C. Unfer, T. Seregina, and C. J. Link. 2005. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes. Cancer Immunol. Immunother. 54: 999-1009.
59. Rossi, G. R., M. R. Mautino, R. C. Unfer, T. M. Seregina, N. Vahanian, and C. J. Link. 2005. Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes. Cancer Res. 65: 10555-10561.
60. Benatuil, L., J. Kaye, R. F. Rich, J. A. Fishman, W. R. Green, and J. Iacomini. 2005. The influence of natural antibody specificity on antigen immunogenicity. Ear. J. Immunol. 35: 2638-2647.
61. Yancey, K. B., C. H. Hammer, L. Harvath, L. Renfer, M. M. Frank, and T. J. Lawley. 1985. Studies of human C5a as a mediator of inflammation in normal human skin. J. Clin. Invest. 75: 486-495.